Interferon
B cell
FOXM1
interferon α
plasmablast
systemic lupus erythematosus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
09
2020
accepted:
15
12
2020
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Systemic lupus erythematosus (SLE) is an autoimmune disease. It is characterized by the production of various pathogenic autoantibodies and is suggested to be triggered by increased type I interferon (IFN) signature. Previous studies have identified increased plasmablasts in the peripheral blood of SLE patients. The biological characteristics of SLE plasmablasts remain unknown, and few treatments that target SLE plasmablasts have been applied despite the unique cellular properties of plasmablasts compared with other B cell subsets and plasma cells. We conducted microarray analysis of naïve and memory B cells and plasmablasts (CD38
Identifiants
pubmed: 33633721
doi: 10.3389/fimmu.2020.498703
pmc: PMC7902015
doi:
Substances chimiques
FOXM1 protein, human
0
Forkhead Box Protein M1
0
Interferon-alpha
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
498703Informations de copyright
Copyright © 2021 Akita, Yasaka, Shirai, Ishii, Harigae and Fujii.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunol Rev. 2019 Mar;288(1):136-148
pubmed: 30874345
Lancet. 2019 Jun 8;393(10188):2344-2358
pubmed: 31180031
J Clin Invest. 1996 Dec 1;98(11):2549-57
pubmed: 8958217
Nat Rev Immunol. 2015 Mar;15(3):160-71
pubmed: 25698678
J Immunol. 1987 Aug 1;139(3):761-6
pubmed: 2439592
Oncol Rep. 2021 Jan;45(1):390-400
pubmed: 33200225
Blood. 2013 Jun 27;121(26):5176-83
pubmed: 23613519
Immunol Rev. 2009 May;229(1):152-72
pubmed: 19426221
Nat Rev Rheumatol. 2011 Mar;7(3):170-8
pubmed: 21283146
Semin Cancer Biol. 2018 Jun;50:77-89
pubmed: 29180117
Biochem Biophys Res Commun. 2001 Jun 15;284(3):583-6
pubmed: 11396940
PLoS One. 2013 Jun 24;8(6):e67003
pubmed: 23826184
Trends Immunol. 2001 Aug;22(8):427-31
pubmed: 11473831
Ann Rheum Dis. 2016 Nov;75(11):2014-2021
pubmed: 27088255
N Engl J Med. 2011 Dec 1;365(22):2110-21
pubmed: 22129255
Ann Rheum Dis. 2015 Jul;74(7):1474-8
pubmed: 25710470
Adv Cancer Res. 2013;118:97-398
pubmed: 23768511
Cells. 2018 May 31;7(6):
pubmed: 29857548
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
pubmed: 12604793
Immunotherapy. 2020 Apr;12(5):275-286
pubmed: 32237942
Annu Rev Immunol. 2011;29:621-63
pubmed: 21314428
Nat Immunol. 2019 Dec;20(12):1631-1643
pubmed: 31740799
Nat Rev Rheumatol. 2019 Jul;15(7):403-412
pubmed: 31165780
Cell Commun Signal. 2018 Sep 12;16(1):57
pubmed: 30208972
Front Immunol. 2018 Mar 05;9:427
pubmed: 29556239
Arthritis Res Ther. 2017 Aug 11;19(1):187
pubmed: 28800777
PLoS Pathog. 2014 Mar 27;10(3):e1003998
pubmed: 24676425
JCI Insight. 2020 Feb 27;5(4):
pubmed: 31971918
J Clin Invest. 2013 Jun;123(6):2464-74
pubmed: 23635775
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
Biochem Pharmacol. 2013 Mar 1;85(5):644-652
pubmed: 23103567
Int Immunol. 2015 Jul;27(7):345-55
pubmed: 25744616
Cancer Res. 2006 Oct 1;66(19):9731-5
pubmed: 17018632
Expert Opin Ther Targets. 2020 Mar;24(3):205-217
pubmed: 32067537
N Engl J Med. 2020 Jan 16;382(3):211-221
pubmed: 31851795
J Immunol Methods. 2009 Jan 1;340(1):42-7
pubmed: 18996127
Nat Rev Rheumatol. 2014 Jun;10(6):365-73
pubmed: 24614588
Arthritis Res Ther. 2013;15 Suppl 1:S2
pubmed: 23566295
Lupus Sci Med. 2019 Aug 13;6(1):e000270
pubmed: 31497305
Immunity. 2003 Aug;19(2):225-34
pubmed: 12932356
Arthritis Rheumatol. 2016 May;68(5):1210-21
pubmed: 26713408
Immunol Cell Biol. 2012 May;90(5):498-504
pubmed: 22430248
PLoS One. 2012;7(9):e44362
pubmed: 23028528
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Sci Transl Med. 2014 Jul 23;6(246):246ra99
pubmed: 25101889
Mol Cancer Res. 2012 Sep;10(9):1189-202
pubmed: 22802261
Clin Rev Allergy Immunol. 2017 Oct;53(2):237-264
pubmed: 28456914
Ann Rheum Dis. 2010 Jan;69(1):305-8
pubmed: 19196727
Nat Commun. 2015 Mar 10;6:6471
pubmed: 25753524
Ann Rheum Dis. 2018 May;77(5):736-743
pubmed: 29437559
Int Immunol. 2002 Apr;14(4):411-9
pubmed: 11934877
Nat Commun. 2014 Nov 12;5:5165
pubmed: 25387393
Mod Rheumatol. 2018 Nov;28(6):986-992
pubmed: 29363990
Cell Cycle. 2009 Jun 15;8(12):1966-7
pubmed: 19411834
J Immunol. 2000 Nov 15;165(10):5970-9
pubmed: 11067960
Immunity. 2020 Jun 16;52(6):1022-1038.e7
pubmed: 32454024
Hematol Oncol. 1986 Apr-Jun;4(2):113-20
pubmed: 2427428
BMC Genomics. 2009 Mar 30;10:137
pubmed: 19331659
J Interferon Cytokine Res. 1999 Apr;19(4):309-18
pubmed: 10334381
Cell. 2016 Apr 21;165(3):551-65
pubmed: 27040498
Arthritis Rheum. 2003 May;48(5):1332-42
pubmed: 12746906
Nat Immunol. 2020 Sep;21(9):1094-1106
pubmed: 32747814
Hum Genomics Proteomics. 2009 Nov 17;2009:
pubmed: 20948567
J Exp Med. 2003 Mar 17;197(6):711-23
pubmed: 12642603
Arthritis Res Ther. 2003;5 Suppl 4:S22-7
pubmed: 15180894